ALK and neoplasm: All trials were designed for testing superiority and included patients of any gender who were aged 18 years or older and had known histologic features (ie, nonsquamous or squamous), PD-L1 tumor expression, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1; trials excluded patients with known EGFR alterations or ALK translocations.